Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. reports recurring business updates as a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. Company updates commonly address financial results, capital-structure actions, medical device portfolio development and subsidiary activity.
News also covers Lucid Diagnostics, PAVmed's commercial-stage cancer prevention diagnostics subsidiary, including EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device activity for patients at risk of esophageal precancer and cancer. Other recurring subjects include Veris Health digital health programs, the Veris Cancer Care Platform, implantable physiological monitor development and PAVmed's endoscopic esophageal imaging technology through Octeris.
Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has completed its previously announced public offering. The company successfully sold 28,750,000 shares of common stock at $1.00 per share, which includes 3,750,000 shares from the full exercise of the underwriters' option.
The offering generated net proceeds of approximately $26.9 million, after deducting underwriting discounts, commissions, and estimated expenses. The funds will be used for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, with Maxim Group LLC as co-manager.
Lucid Diagnostics (NASDAQ: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), has announced the pricing of its public offering of 25 million shares of common stock at $1.00 per share.
The company expects to raise approximately $25.0 million in gross proceeds, with an additional 30-day option granted to underwriters to purchase up to 3.75 million additional shares. The offering, managed by Canaccord Genuity LLC and BTIG, LLC as joint bookrunners, is expected to close around September 11, 2025. Proceeds will be used for working capital and general corporate purposes.
Lucid Diagnostics (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), has announced plans for an underwritten public offering of common stock. The offering includes a 30-day option for underwriters to purchase additional shares.
The offering will be managed by Canaccord Genuity LLC and BTIG, LLC as joint bookrunners, with Maxim Group LLC as co-manager. Proceeds will support working capital and general corporate purposes. The offering will be made under an effective S-3 shelf registration statement, with timing, size, and terms subject to market conditions.
Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ:PAVM), has scheduled an investor conference call for Monday, September 8, 2025, at 8:30 AM ET.
The call will discuss the September 4 MolDX Contractor Advisory Committee (CAC) meeting regarding the reconsideration of Local Coverage Determination (LCD) L39256 for Lucid's EsoGuard® Esophageal DNA Test. Investors can join via webcast or dial in using 1-800-836-8184 (US) or 1-646-357-8785 (international). A 90-day replay will be available on the company's investor relations website.
Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ:PAVM), announced its participation in the upcoming Cantor Global Healthcare Conference 2025.
Chairman and CEO Lishan Aklog, M.D. will engage in a fireside chat on September 5, 2025, at 8:35 AM EDT in New York. The 30-minute presentation will be available via webcast, with a replay accessible through the company's Investor Relations website for 30 days after the event.
PAVmed (Nasdaq: PAVM) has signed a non-binding letter of intent with Duke University to license groundbreaking endoscopic imaging technology through a new subsidiary. The technology combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT) to identify and treat esophageal precancer during upper endoscopy.
The technology, developed by Duke's Dr. Adam Wax in partnership with Dr. Nicholas Shaheen, has demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes. This innovative approach could replace traditional biopsies, enabling real-time detection and immediate treatment during the same endoscopic procedure.
Under the proposed agreement, PAVmed's subsidiary will receive exclusive worldwide license rights to the intellectual property. The company expects this technology to complement its EsoGuard diagnostic platform and attract strategic interest from endoscopic ablation companies.
PAVmed (NASDAQ: PAVM) reported its Q2 2025 financial results and business updates. Key highlights include Lucid Diagnostics processing 2,756 EsoGuard® tests with revenue of $1.2 million. The company reported a GAAP net loss of $13.3 million, or $(0.74) per share.
Significant developments include Lucid securing a CAC meeting for Medicare LCD coverage, strengthening its balance sheet with a $16.1 million public offering, and initiating testing under its first positive commercial insurance coverage with Highmark Blue Cross Blue Shield. Veris Health completed $2.5 million direct equity financing and established a strategic partnership with Ohio State's James Cancer Hospital.
The company ended Q2 2025 with cash and equivalents of $4.0 million, compared to $1.2 million at the end of 2024. Operating expenses were $4.7 million, including $0.2 million in stock-based compensation.
Lucid Diagnostics (Nasdaq: LUCD) reported its Q2 2025 financial results, highlighting $1.2 million in revenue from 2,756 processed EsoGuard® tests. The company strengthened its balance sheet through a public offering, netting $16.1 million and ending Q2 with over $30 million in proforma cash, extending runway into 2026.
Key developments include a scheduled Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 for Medicare coverage consideration, initiation of testing under Highmark Blue Cross Blue Shield coverage, and a partnership with Hoag healthcare network. The company reported a GAAP net loss of $7.9 million ($0.08 per share) and non-GAAP adjusted loss of $9.9 million ($0.10 per share) for Q2 2025.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences in August 2025.
The company will attend the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference for one-on-one meetings on August 11-12, 2025. Additionally, management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 2:30 PM ET in Boston, MA. The Canaccord presentation will be available via webcast with a 30-day replay option.
PAVmed (Nasdaq: PAVM), a diversified commercial-stage medical technology company, has scheduled a business update conference call and webcast for August 14, 2025, at 8:30 AM ET. During the call, Chairman and CEO Dr. Lishan Aklog will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present Q2 2025 financial results.
Investors can access the webcast through PAVmed's investor relations website. For telephone access, U.S. callers should dial 1-800-836-8184, while international callers can use 1-646-357-8785. A 30-day replay will be available on the company website following the call.